Search 

As an investment and management platform established by UK-listed company Cathay International Holdings Limited, Lansen has built up pharmaceutical segment, health segemtn and cosmetic segment. Lansen has been listed in Stock Exchange of Hong Kong Limited (SEHK) on May 7, 2010. Lansen's top products are in rheumatology and dermatology area, and Lansen has established an extensive distribution network, with more than 300 frontline sales staff and more than 1500 distributors. By licensing in promising products at commercial stage and clinical stage, or other cooperation patterns, Lansen plans to expand to more diseases medication market, including rheumaotlogy, dermatology, orthopedics and nephrology.

Luoxin is an A share listed pharma with focus on Respiratory, GI, infectious disease as well as on oncology.

Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of over 30 drug candidates in China and more than 10 drug candidates in other international markets. Along with a number of new drugs and new formulations in the central nervous system and oncology therapeutic areas under study in the U.S. Europe and Japan, Luye Pharma has reached high-level international standards in novel drug delivery technologies including microspheres, liposomes, and transdermal drug delivery systems, as well as actively making strategic developments in the fields of biological antibodies, cell therapies and gene therapies, among others.

 

Luye Pharma is developing a global supply chain of 8 manufacturing sites with over 30 production lines in total, establishing GMP quality management and international standard control systems. With more than 30 products covering the central nervous system, oncology, cardiovascular, metabolism and other therapeutic areas, business is conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets - China, the U.S., Europe and Japan, as well as in fast growing emerging markets.

Investment banking boutique specialized in cross-border medical device transactions.
We would like to bring to your next events exclusive opportunities from Western companies in the fields of: robotics, cancer screening, liver disease diagnostic, robotics, cardiovascular and respiratory

Global leading Medtech company

Nuance Biotech (Shanghai) Co. Ltd was founded in 2014.
Leading China based biotech company focussed on commercial, regulatory and development stage assets.
Nuance is directed by a world class board of directors and managed by an experienced China based management team with a strong track record. Backed a leading global tier 1 investor with more than USD 1 billion under management in China – Matrix Partners. The company strategy and approach allows for a highly scalable commercial and drug development model i.e. ability to run multiple initiatives.

Reistone BioPharma is a clinical-stage biotech company focused on developing innovative medicines in autoimmune and autoinflammatory diseases. We are headquartered in Shanghai, China and have offices in Beijing, China as well in Boston and Chicago, US. Our current pipeline includes 4 small molecules in autoimmune and inflammatory diseases where significant gaps exist. The leading asset, a potent selective JAK1 inhibitor, recently completed global phase 2 trials in China, US and Europe in atopic dermatitis, ulcerative colitis and Crohn’s disease.

Currently we are looking for either partnership to develop the AD and/or UC or CD indications for phase 3 or out-license the global right excluding China market.

The Research Institute of Tsinghua University in Shenzhen (RITS) was founded in 1996. RITS strives to establish an innovation incubation system and an industrial investment platform open to both China and abroad, cultivating strategic emerging industries.

Fenglin Biomedical Center (BioFM) is an innovation platform based in Xuhui Shanghai, which functions as the China soft-landing gateway for oversea bio-medical companies. It provides working spaces in downtown area in a flexible manner and helps clients increase their business value with professional services and by leveraging innovative resources including academics, hospitals, industries and venture capitals in the region. Different from the traditional accelerators and incubators, BioFM aims to be a boutique and unique service provider especially for bio-medical entrepreneurs, doctors, and scientists, while helping overseas companies and start-ups to develop their business in China quicker and better

Founded in 1990, Zhejiang Jingxin Pharmaceutical Co., Ltd. is a listed pharmaceutical company integrating R&D, production and sales.
The company is a national key high-tech enterprise, with a national enterprise technology center, post-doctoral research station, provincial key enterprise research institute, provincial academician expert workstation, provincial high-tech enterprise R & D center, and Shanghai Research Institute in Shanghai Zhangjiang Hi-Tech Park.
Jingxin Pharmaceutical adheres to the mission of meticulously guarding health and is committed to becoming a front runner in neurological and cardiovascular therapy areas in China.
No. 70 pharmaceutical companies in China.